Distinguished in Salpingo-Oophorectomy

Dr. Douglas A. Levine

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
1275 York Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Salpingo-Oophorectomy
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Douglas Levine is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Levine is rated as a Distinguished provider by MediFind in Oophorectomy. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Oophorectomy, and Salpingo-Oophorectomy.

His clinical research consists of co-authoring 221 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 3 clinical trials in the study of Oophorectomy.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

1275 York Ave, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
WISP (Women Choosing Surgical Prevention)
WISP (Women Choosing Surgical Prevention)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine, Poly ICLC
Study Phase: Phase 1/Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 10, 2020
View 5 Less Clinical Trials

221 Total Publications

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Journal: Nature communications
Published: September 09, 2025
Similar Doctors
Elite in Salpingo-Oophorectomy
Dr. Jason D. Wright
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Elite in Salpingo-Oophorectomy
Dr. Jason D. Wright
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Trustees Of Columbia University In The City Of New York

51 W 51st St, Fl 3 Suite 360, 
New York, NY 
 (1.3 miles away)
212-326-8426
Languages Spoken:
English
See accepted insurances

Jason Wright is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Wright is rated as an Elite provider by MediFind in Oophorectomy. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Oophorectomy.

Distinguished in Salpingo-Oophorectomy
Dr. Noah D. Kauff
Gynecologic Oncology | Medical Genetics | Obstetrics and Gynecology
Distinguished in Salpingo-Oophorectomy
Dr. Noah D. Kauff
Gynecologic Oncology | Medical Genetics | Obstetrics and Gynecology

North Shore Health System Medical Faculty Group Practice Inc

27005 76th Ave, 
New Hyde Park, NY 
 (13.0 miles away)
718-470-4449
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noah Kauff is a Gynecologic Oncologist and a Medical Genetics provider in New Hyde Park, New York. Dr. Kauff is rated as a Distinguished provider by MediFind in Oophorectomy. His top areas of expertise are Ovarian Cancer, DICER1 Syndrome, BRCA Positive Breast Cancer, Oophorectomy, and Salpingo-Oophorectomy. Dr. Kauff is currently accepting new patients.

Distinguished in Salpingo-Oophorectomy
Dr. Kevin M. Holcomb
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Salpingo-Oophorectomy
Dr. Kevin M. Holcomb
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

North Shore-Lij Medical PC

27005 76th Ave Gf, 
New Hyde Park, NY 
 (14.5 miles away)
718-470-7501
Languages Spoken:
English
See accepted insurances

Kevin Holcomb is a Gynecologic Oncologist and an Oncologist in New Hyde Park, New York. Dr. Holcomb is rated as a Distinguished provider by MediFind in Oophorectomy. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Oophorectomy, and Salpingo-Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levine's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile